查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193044

肝病诊断市场：按技术（成像,实验室测试,内窥镜检查,活检）,最终用户（医院,实验室等）分类：全球机会分析和行业预测2021-2031

Liver Disease Diagnostics Market By Technique (imaging, laboratory tests, endoscopy, biopsy), By End Use (hospitals, laboratories, others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 203 Pages | 商品交期: 2-3个工作天内

价格

肝病诊断市场预计将在 2021 年达到 345.204 亿美元，到 2031 年达到 619.621 亿美元，从 2022 年到 2031 年的复合年增长率为 6.1%。

肝臟是人体的重要器官，具有 500 多种功能，主要功能包括胆汁的产生和排洩，胆汁以胆红素,胆固醇,激素和药物的形式排出体外。 它可以抵抗感染,排除毒素并帮助净化血液。 肝病由多种影响肝臟的复杂疾病组成。 肝功能障碍是致命的，可导致甲型肝炎,乙型肝炎,丙型肝炎,非酒精性脂肪肝,肝癌,胆管癌,肝细胞腺瘤,肝硬化等多种急慢性疾病。 肝病的原因包括感染（寄生虫,病毒）,慢性酒精中毒,肝臟脂肪堆积,免疫系统异常和遗传（血色素沉着症,高氧尿症,威尔逊氏病）。

诊断肝病的方法有多种，例如影像学检查,临床检查,内窥镜检查和活组织检查。 越来越多地使用诊断成像，如 MRI,CT 扫描和实验室诊断肝病，正在推动肝病诊断市场的增长。

推动肝病诊断市场增长的主要因素包括不断进步的技术进步,肝炎,慢性乙型肝炎,慢性丙型肝炎,非酒精性脂肪肝 (NAFLD) 等慢性肝病。例如，疾病的流行正在上升。 其他肝病包括浸润性肝病（肝结节病,淀粉样变性等）,ALPHA-1抗胰蛋白□缺乏症,原发性胆汁性胆管炎,原发性硬化性胆管炎。

例如，根据世界卫生组织 (WHO) 于 2022 年 6 月发布的一份报告，全球估计有 5800 万人感染了慢性丙型肝炎病毒，每年约有 150 万新病例。和 估计有 320 万青少年和儿童感染慢性丙型肝炎。 这些因素增加了对肝病诊断剂的需求。

然而，不利的医疗费用,训练有素的医生和内窥镜医师短缺,活检副作用以及与肝病诊断相关的高成本等并发症预计会阻碍市场增长。 另一方面，发展中国家未被满足的医疗需求和新兴国家有利的商机，未来有望为全球肝病诊断药物生产企业带来巨大商机。

此外，由于慢性肝病,肝炎和肝癌的患病率上升，对药物发现和开发的研发投资不断增加，以及对肝病微创诊断方法的认识不断提高，预计医疗保健业务将会增长。因此，预计主要参与者在预测期内对该市场的投资将提供有利可图的机会。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章肝病诊断市场：按技术分类

  • 概览
    • 市场规模和预测
  • 成像
    • 主要市场趋势,增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 实验室测试
    • 主要市场趋势,增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 内窥镜检查
    • 主要市场趋势,增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 活检
    • 主要市场趋势,增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章肝病诊断市场：按最终用户分类

  • 概览
    • 市场规模和预测
  • 医院
    • 主要市场趋势,增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 实验室
    • 主要市场趋势,增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势,增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章肝病诊断市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按技术分类
    • 北美市场规模和预测：按最终用户分类
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按技术分类
    • 欧洲市场规模和预测：按最终用户分类
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机遇
    • 亚太市场规模和预测：按技术分类
    • 亚太市场规模和预测：按最终用户分类
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 中国
      • 日本
      • 印度
      • 韩国
      • 澳大利亚
      • 亚太其他地区
  • 拉美
    • 主要趋势和机遇
    • LAMEA 市场规模和预测：按技术分类
    • LAMEA 市场规模和预测：按最终用户分类
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉美地区

第七章商业条件

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第八章公司简介

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Cosara Diagnostics Pvt Ltd
  • Echosens
  • Meril Life Sciences Pvt. Ltd.
  • PerkinElmer
  • Qiagen N.V.
  • Siemen's AG
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
Product Code: A08425

The liver disease diagnostics market was valued at $34,520.4 million in 2021 and is estimated to reach $61,962.1 million by 2031, growing at a CAGR of 6.1% from 2022 to 2031. 

The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson's disease)

Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.

Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e.g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.

For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.

However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the liver disease diagnostics market analysis from 2021 to 2031 to identify the prevailing liver disease diagnostics market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technique

  • endoscopy
  • biopsy
  • imaging
  • laboratory tests

By End Use

  • hospitals
  • laboratories
  • others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbott Laboratories
    • Bio-Rad Laboratories Inc.
    • Cosara Diagnostics Pvt Ltd
    • Echosens
    • Meril Life Sciences Pvt. Ltd.
    • PerkinElmer
    • Qiagen N.V.
    • Siemen's AG
    • Thermo Fisher Scientific Inc.
    • Trivitron Healthcare

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 imaging
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 laboratory tests
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 endoscopy
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 biopsy
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: LIVER DISEASE DIAGNOSTICS MARKET, BY END USE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 hospitals
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 laboratories
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: LIVER DISEASE DIAGNOSTICS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Technique
    • 6.2.3 North America Market size and forecast, by End Use
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Technique
      • 6.2.4.1.2 Market size and forecast, by End Use
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Technique
      • 6.2.4.2.2 Market size and forecast, by End Use
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Technique
      • 6.2.4.3.2 Market size and forecast, by End Use
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Technique
    • 6.3.3 Europe Market size and forecast, by End Use
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Technique
      • 6.3.4.1.2 Market size and forecast, by End Use
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Technique
      • 6.3.4.2.2 Market size and forecast, by End Use
      • 6.3.4.3 UK
      • 6.3.4.3.1 Market size and forecast, by Technique
      • 6.3.4.3.2 Market size and forecast, by End Use
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Market size and forecast, by Technique
      • 6.3.4.4.2 Market size and forecast, by End Use
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Market size and forecast, by Technique
      • 6.3.4.5.2 Market size and forecast, by End Use
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Technique
      • 6.3.4.6.2 Market size and forecast, by End Use
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Technique
    • 6.4.3 Asia-Pacific Market size and forecast, by End Use
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Market size and forecast, by Technique
      • 6.4.4.1.2 Market size and forecast, by End Use
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Market size and forecast, by Technique
      • 6.4.4.2.2 Market size and forecast, by End Use
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Technique
      • 6.4.4.3.2 Market size and forecast, by End Use
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Market size and forecast, by Technique
      • 6.4.4.4.2 Market size and forecast, by End Use
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Market size and forecast, by Technique
      • 6.4.4.5.2 Market size and forecast, by End Use
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Market size and forecast, by Technique
      • 6.4.4.6.2 Market size and forecast, by End Use
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Technique
    • 6.5.3 LAMEA Market size and forecast, by End Use
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Technique
      • 6.5.4.1.2 Market size and forecast, by End Use
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Technique
      • 6.5.4.2.2 Market size and forecast, by End Use
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Market size and forecast, by Technique
      • 6.5.4.3.2 Market size and forecast, by End Use
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Market size and forecast, by Technique
      • 6.5.4.4.2 Market size and forecast, by End Use

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Abbott Laboratories
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Bio-Rad Laboratories Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Cosara Diagnostics Pvt Ltd
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Echosens
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Meril Life Sciences Pvt. Ltd.
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 PerkinElmer
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Qiagen N.V.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Siemen's AG
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 Thermo Fisher Scientific Inc.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Trivitron Healthcare
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 2. LIVER DISEASE DIAGNOSTICS MARKET, FOR IMAGING, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. LIVER DISEASE DIAGNOSTICS MARKET FOR IMAGING, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORY TESTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET, FOR ENDOSCOPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. LIVER DISEASE DIAGNOSTICS MARKET FOR ENDOSCOPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. LIVER DISEASE DIAGNOSTICS MARKET, FOR BIOPSY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. LIVER DISEASE DIAGNOSTICS MARKET FOR BIOPSY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 11. LIVER DISEASE DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. LIVER DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. LIVER DISEASE DIAGNOSTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. LIVER DISEASE DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. LIVER DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 22. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 24. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 32. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 34. UK LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 35. UK LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 36. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 37. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 38. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 39. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 40. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 41. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 42. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 43. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 44. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 45. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 46. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 47. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 48. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 49. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 50. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 51. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 52. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 53. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 54. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 55. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 56. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 57. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 58. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 59. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 60. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 61. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 62. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 63. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 64. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 66. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 67. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 68.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 69.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 70.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 71.ABBOTT LABORATORIES: NET SALES,
  • TABLE 72.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 73.BIO-RAD LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 74.BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 75.BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 76.BIO-RAD LABORATORIES INC.: NET SALES,
  • TABLE 77.BIO-RAD LABORATORIES INC.: KEY STRATERGIES
  • TABLE 78.COSARA DIAGNOSTICS PVT LTD: COMPANY SNAPSHOT
  • TABLE 79.COSARA DIAGNOSTICS PVT LTD: OPERATING SEGMENTS
  • TABLE 80.COSARA DIAGNOSTICS PVT LTD: PRODUCT PORTFOLIO
  • TABLE 81.COSARA DIAGNOSTICS PVT LTD: NET SALES,
  • TABLE 82.COSARA DIAGNOSTICS PVT LTD: KEY STRATERGIES
  • TABLE 83.ECHOSENS: COMPANY SNAPSHOT
  • TABLE 84.ECHOSENS: OPERATING SEGMENTS
  • TABLE 85.ECHOSENS: PRODUCT PORTFOLIO
  • TABLE 86.ECHOSENS: NET SALES,
  • TABLE 87.ECHOSENS: KEY STRATERGIES
  • TABLE 88.MERIL LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 89.MERIL LIFE SCIENCES PVT. LTD.: OPERATING SEGMENTS
  • TABLE 90.MERIL LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 91.MERIL LIFE SCIENCES PVT. LTD.: NET SALES,
  • TABLE 92.MERIL LIFE SCIENCES PVT. LTD.: KEY STRATERGIES
  • TABLE 93.PERKINELMER: COMPANY SNAPSHOT
  • TABLE 94.PERKINELMER: OPERATING SEGMENTS
  • TABLE 95.PERKINELMER: PRODUCT PORTFOLIO
  • TABLE 96.PERKINELMER: NET SALES,
  • TABLE 97.PERKINELMER: KEY STRATERGIES
  • TABLE 98.QIAGEN N.V.: COMPANY SNAPSHOT
  • TABLE 99.QIAGEN N.V.: OPERATING SEGMENTS
  • TABLE 100.QIAGEN N.V.: PRODUCT PORTFOLIO
  • TABLE 101.QIAGEN N.V.: NET SALES,
  • TABLE 102.QIAGEN N.V.: KEY STRATERGIES
  • TABLE 103.SIEMEN'S AG: COMPANY SNAPSHOT
  • TABLE 104.SIEMEN'S AG: OPERATING SEGMENTS
  • TABLE 105.SIEMEN'S AG: PRODUCT PORTFOLIO
  • TABLE 106.SIEMEN'S AG: NET SALES,
  • TABLE 107.SIEMEN'S AG: KEY STRATERGIES
  • TABLE 108.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 109.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 110.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 111.THERMO FISHER SCIENTIFIC INC.: NET SALES,
  • TABLE 112.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 113.TRIVITRON HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 114.TRIVITRON HEALTHCARE: OPERATING SEGMENTS
  • TABLE 115.TRIVITRON HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 116.TRIVITRON HEALTHCARE: NET SALES,
  • TABLE 117.TRIVITRON HEALTHCARE: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
  • FIGURE 3.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.LIVER DISEASE DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.LIVER DISEASE DIAGNOSTICS MARKET,BY TECHNIQUE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF IMAGING LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BIOPSY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 17.LIVER DISEASE DIAGNOSTICS MARKET,BY END USE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF LABORATORIES LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 21.LIVER DISEASE DIAGNOSTICS MARKET BY REGION,2021
  • FIGURE 22.U.S. LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 23.CANADA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 24.MEXICO LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 25.GERMANY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 26.FRANCE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 27.UK LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 28.ITALY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.SPAIN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.CHINA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.INDIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.BRAZIL LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45.COMPETITIVE DASHBOARD
  • FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 48.BIO-RAD LABORATORIES INC..: NET SALES ,($MILLION)
  • FIGURE 49.COSARA DIAGNOSTICS PVT LTD.: NET SALES ,($MILLION)
  • FIGURE 50.ECHOSENS.: NET SALES ,($MILLION)
  • FIGURE 51.MERIL LIFE SCIENCES PVT. LTD..: NET SALES ,($MILLION)
  • FIGURE 52.PERKINELMER.: NET SALES ,($MILLION)
  • FIGURE 53.QIAGEN N.V..: NET SALES ,($MILLION)
  • FIGURE 54.SIEMEN'S AG.: NET SALES ,($MILLION)
  • FIGURE 55.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
  • FIGURE 56.TRIVITRON HEALTHCARE.: NET SALES ,($MILLION)